CTRI/2010/091/001351已完成1 期
An open labeled, non- comparative, single center study to assess the efficacy and safety of atropine sulfate by inhalation in healthy human volunteers
Defence R&D Organisation0 个研究点目标入组 6 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male healthy human volunteers, 18-65 years of age, body weight of 50-70kg
排除标准
- •1. Volunteers who are unwilling to give informed consent.
- •2. Volunteers taking any medication or having URI/lung infection at time of study.
- •3. Volunteers with significant dyspnea or cough due to any cause.
- •4. Volunteers having any contraindications like increased intraocular pressure (IOP), lung disease, unstable cardiac rhythm, tachycardia etc
- •5. Volunteers who have compromised lung function due to any cause
- •6. Volunteers who have any medical condition which in the judgment of the investigator may render them in appropriate for participation in the trial
研究者
相似试验
已完成
1 期
A clinical trial to assess the bioavailability and safety of nano-atropine sulfate by dry powder inhalation in healthy human volunteers for nerve gas poisoningCTRI/2010/091/001350Defence R&D Organisation6
已完成
1 期
A clinical trial to assess the bioavailability and safety of atropine sulfate injected by sublingual submucosal injection in healthy human volunteers for nerve gas poisoningCTRI/2010/091/001352Defence R&D Organisation6
已完成
1 期
A clinical trial to assess the bioavailability and safety of atropine sulfate by intranasal drops in healthy human volunteers for nerve gas poisoningCTRI/2010/091/001347Defence R&D Organisation6
尚未招募
3 期
single-dose clinical study evaluating efficacy and safety of standard intramuscular preparation of Paracetamol available in the market for the management of feverCTRI/2018/10/016216Troikaa Pharmaceuticals Limited
进行中（未招募）
1 期
A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of MLD patients with high residual level of voluntary functioEUCTR2007-007165-20-DKShire Pharmaceuticals Ireland Limited6